CagriSema is one pen carrying two separate appetite hormones, not a new single molecule. Novo Nordisk pairs cagrilintide, a long-acting amylin analog, with semaglutide, the GLP-1 receptor agonist already licensed for type 2 diabetes and for obesity, at 2.4 mg of each once a week. The evidence base is phase 3 and substantial, but the product holds no marketing authorization anywhere, which is the single fact consumer coverage most often gets wrong.
CagriSema is an investigational once-weekly fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg that reported a 20.4 percent average body weight reduction at 68 weeks in REDEFINE 1 against 3.0 percent for placebo.
Native amylin is co-secreted with insulin after a meal and helps end that meal, then clears from the blood within minutes, which is why the hormone itself was never workable as a weekly medicine. Cagrilintide is that molecule rebuilt around the problem: the peptide backbone is stabilized against aggregation and a fatty acid chain binds it reversibly to circulating albumin. The distinction matters when reading combination results, because the published record puts cagrilintide on its own well past the threshold of an active weight-lowering agent rather than a passenger.
Cagrilintide is a long-acting amylin analogue that produced average weight reductions of roughly 6 to 11 percent as weekly monotherapy over 26 weeks in phase 2 dose-finding work, and it holds no marketing approval in any jurisdiction.
Semaglutide is the most thoroughly documented weight-lowering peptide in circulation, carrying approvals, cardiovascular outcome trials and years of prescribing behind it. The same record also shows a ceiling: average reductions in the mid-teens as a percentage of body weight over roughly a year and a half, wide variation between individuals, and typical regain after discontinuation. That ceiling is the gap a second appetite hormone was added to close.
Semaglutide 2.4 mg produces average body weight reductions in the mid-teens as a percentage of starting weight over roughly 18 months, and weight regain after discontinuation is the typical pattern.
Two hormones that suppressed appetite through the same circuit would be redundant, and amylin and GLP-1 are not. GLP-1 signalling concentrates in hypothalamic and hindbrain circuits governing food reward and gastric emptying, while amylin arrives largely through the area postrema and interacts with leptin sensitivity and the mechanisms that defend body weight after loss. Phase 2 data on the pair showed effects closer to additive than redundant, which is the argument for one device instead of two.
Because CagriSema is a fixed-ratio co-formulation, a participant who tolerates one component poorly steps down both, and the share of late-stage trial participants who stayed below the top dose pulled the reported group average downward.
Regulatory status is the detail consumer coverage most often misreports, so it is worth stating flatly: CagriSema is investigational and cannot be prescribed or dispensed as an approved medicine. Novo Nordisk owns both components, semaglutide from its incretin franchise and cagrilintide from its amylin programme, which is why a proprietary single-pen co-formulation was possible without a partnership. The company has filed for regulatory review on the strength of the REDEFINE programme, and a submission is a request rather than a decision.
CagriSema holds no marketing authorization from the United States Food and Drug Administration or the European Medicines Agency, and cagrilintide has never been approved as a standalone medicine in any jurisdiction.
Every weekly incretin pen shares one design constraint, and this one is no exception: the top dose is tolerable only if it is reached slowly, because the gastrointestinal effects of both hormone pathways are strongly dose and rate dependent. The pivotal protocols climb to 2.4 mg of each peptide over roughly four months, and the trials also document what happens when that climb goes badly.
The phase 3 protocols reach the 2.4 mg cagrilintide plus 2.4 mg semaglutide target through a stepwise escalation of roughly four months, and dosing, titration and storage for any approved version will come from the regulator-approved label rather than trial protocols.
REDEFINE 1 recorded one of the largest average weight reductions ever produced by a drug in an obesity trial, and it was still read as a miss. Earlier guidance had pointed toward figures around 25 percent, and the primary treatment-policy analysis returned 20.4 percent. The distance between that number and the 22.7 percent on-treatment figure is largely a question of who stayed on dose, not of how the drug behaves at full exposure.
REDEFINE 1 reported a 20.4 percent average body weight reduction at 68 weeks under the treatment-policy estimand and 22.7 percent among participants who stayed on treatment, while REDEFINE 2 in type 2 diabetes reported roughly 14 percent.
Cross-trial rankings are the least reliable numbers in this field. Enrolment criteria, baseline weight, run-in periods, lifestyle intervention intensity, trial duration and the choice of estimand each shift a result by several percentage points, which is why regulators and guideline bodies place little weight on them. The differences that hold up are mechanistic and evidentiary rather than decimal places on an average.
| Criteria | CagriSema | Semaglutide 2.4 mg | Tirzepatide |
|---|---|---|---|
| Mechanism | Amylin analogue plus GLP-1 agonist | GLP-1 agonist | GIP and GLP-1 dual agonist |
| Formulation | Two peptides, fixed-dose co-formulation | Single peptide | Single peptide |
| Reported average weight reduction | 20.4% at 68 weeks (REDEFINE 1) | Mid-teens percent | Low to mid twenties percent |
| Dominant adverse effects | Dose-dependent nausea, vomiting, constipation | Same class profile | Same class profile |
| Regulatory status | Investigational | Approved | Approved |
Semaglutide carries established cardiovascular outcome evidence in its approved indications, while outcome data specific to the combination remain to be generated, so CagriSema's case currently rests on weight reduction alone.
Gastrointestinal effects dominate the reported safety picture, as they do across the whole incretin class, and they cluster during escalation rather than persisting. The more telling figure in the trials was not how many participants discontinued, which was a minority, but how many finished below target dose, since a fixed ratio turns a tolerability problem into reduced exposure to both drugs at once. None of this replaces individual medical advice from a clinician who knows the patient's history.
The fixed-ratio design means a tolerability problem reduces exposure to both peptides at once, and class labeling for approved GLP-1 receptor agonists carries warnings for pancreatitis, gallbladder disease, diabetic retinopathy complications and medullary thyroid carcinoma.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
